

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA selpercatinib for treating advanced thyroid cancer with RET alterations

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when no ACD was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

During the scoping process it was identified that there are barriers to access (and extremely limited treatment options) for people under the age of 18 who have these types of thyroid cancer. Clinical and patient experts at the scoping workshop raised the potential for both of the indications to incorporate people under the age of 18. The committee recognised that only the marketing authorisation for advanced RET-mutant medullary thyroid cancer (MTC) allows for treatment of young people age 12 and above.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

None raised.

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A.

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

N/A.

Approved by Associate Director (name): Jasdeep Hayre

Date: 24 September 2021